Allison L. Zulli

机构：VenatoRx Pharmaceuticals (United States)

发表论文 26 篇 · 总被引 589 次 · h-index 13

代表论文

• The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity (2007 · Molecular Cancer Therapeutics · 被引 112)
• A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5- a ]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779 (2012 · Journal of Medicinal Chemistry · 被引 64)
• Optimization of the β-Aminoester class of factor Xa inhibitors. part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity (2002 · Bioorganic & Medicinal Chemistry Letters · 被引 53)
• Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes (2021 · Journal of Medicinal Chemistry · 被引 48)
• Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 1: SAR Exploration and Effective Bioisosteric Replacement of a phenyl substituent (2003 · Bioorganic & Medicinal Chemistry Letters · 被引 45)
• The preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity (1997 · Bioorganic & Medicinal Chemistry Letters · 被引 45)